Sinopharm Modern (600420.SH) Announces Approval of Olopatadine Hydrochloride Eye Drops Registration

Intelligent Finance APP News, SHANGHAI MODERN PHARMACEUTICAL CO LTD (600420.SH) announced that recently, its holding subsidiary Three Pharmaceutical Drug Group (Wuhu) Co., LTD ("Three Pharmaceutical") has received the "Drug Registration Certificate" for Olopatadine Hydrochloride Eye Drops issued by the National Medical Products Administration. It is reported that Olopatadine Hydrochloride Eye Drops are used to treat the signs and symptoms of allergic conjunctivitis. According to the Mienet database, the sales revenue of Olopatadine Hydrochloride Eye Drops in public hospitals in China in 2023 was RMB 139.8 million.